Latest Licensing News

Sunrise Energy Metals has announced a significant 87% increase in the Ore Reserve Estimate for its Syerston Scandium Project, underpinning a 32-year mine life with steady scandium oxide production. The update comes amid tightening Chinese export controls, positioning the project as a critical non-Chinese scandium supply source.

Etherstack has secured a £14.2 million contract with the UK Home Office to provide critical software for the Emergency Services Network, reinforcing its global leadership in public safety communications.

Peppermint Innovation is repositioning as a digital wallet operator targeting the vast Philippine cooperative sector, aiming to scale rapidly and generate predictable revenue from one million active users.

Latitude 66 has inked a binding deal with Iondrive to test innovative Deep Eutectic Solvent technology on cobalt concentrates from its Finnish KSB Project, aiming to boost cost-efficiency and sustainability in critical minerals refining.

Gold Mountain Limited has reported significant extensions to its rare earth mineralisation at the Irajuba Down Under Project in Brazil, confirming high-grade total and magnet rare earth oxides and paving the way for resource drilling.

Singular Health Group has advanced its US expansion through the deployment of 3DICOM™ licenses under a key contract with Provider Network Solutions, alongside appointing a new US commercial chief to drive growth.

AdAlta Limited has raised up to A$1.1 million through a private placement, boosting its war chest to advance innovative cellular immunotherapy projects targeting solid cancers.

Wellnex Life reported an 18.2% sales decline in Q1 FY26 amid delayed IP licensing revenue and increased costs, while securing new debt facilities and exiting the medicinal cannabis segment.

Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.

Race Oncology showcased compelling preclinical data at ESMO 2025 revealing that their drug RC220, combined with doxorubicin, not only shields the heart from toxicity but also boosts anticancer effects, supporting ongoing clinical trials.

BrainChip Holdings Ltd showcased its leadership in ultra-low-power edge AI technology, emphasizing strong partnerships and a growing product portfolio targeting high-growth sectors like defense and healthcare.

BrainChip Holdings has initiated tape-out for its AKD1500 neuromorphic AI chip, targeting volume production by late Q3 2026 to meet rising demand for ultra-low-power edge AI solutions.